首页> 外国专利> PHARMACOLOGICAL COMPOSITION, APPLICATION OF AN AGENT IN PRODUCTION OF A DRUG, METHOD OF THERAPEUTICALLY TREATING FEMALE PATIENTS, TESTING METHOD IN ORDER TO IDENTIFY SAID AGEND, METHOD OF IDENTIFYING SAID AGENT, DIAGNOSING METHOD, DIAGNOSTIC COMPOSITION, ANIMAL MODEL FOR USE IN IDENTIFICATION OF SAID AGENT AND METHOD OF OBTAINING A DRUG

PHARMACOLOGICAL COMPOSITION, APPLICATION OF AN AGENT IN PRODUCTION OF A DRUG, METHOD OF THERAPEUTICALLY TREATING FEMALE PATIENTS, TESTING METHOD IN ORDER TO IDENTIFY SAID AGEND, METHOD OF IDENTIFYING SAID AGENT, DIAGNOSING METHOD, DIAGNOSTIC COMPOSITION, ANIMAL MODEL FOR USE IN IDENTIFICATION OF SAID AGENT AND METHOD OF OBTAINING A DRUG

机译：药物成分，药物生产中药物的应用，对女性患者进行治疗性治疗的方法，用于确定该目的的检测方法，用于确定该目标的方法，用于诊断的方法，用于该目标的诊断方法，用于该目标的动物模型和获取药物的方法

页面导航

摘要
著录项
相似文献

摘要

A pharmaceutical composition (C1) comprising an inhibitor of neutral endopeptidase (NEP) (a1) with carrier, diluent or excipient optionally with additional pharmaceutical agent (preferably NEP, phosphodiesterase (PDE) and/or neuropeptide Y (NPY) inhibitor), is new. Independent claims are included for: (1) performing an assay method for identifying an agent that can be used to treat female sexual dysfunction (FSD) involving determining whether an agent can directly or indirectly potentiate cyclic adenosine-3',5'-monophosphate (cAMP) where a potentiation of cAMP in the presence of the agent is indicative that the agent can be useful in the treatment of FSD where the agent is (a1), identifying at least one agent that can directly or indirectly potentiate cAMP, preparing the identified agents, mixing the identified agent with carrier, diluent or excipient to form (C1), and packaging (C1); (2) an assay process for identifying an agent that can treat FSD involving administering an agent to an animal model, measuring any potentiation of cAMP and/or increase in blood flow in the genitalia of the animal, where the agent is (a1) and the animal model comprises at least one of an anesthetized female animal including device to measure changes in genital blood flow of the animal following stimulation of the pelvic nerve where the agent potentiates cAMP in the sexual genitalia following optionally oral administration; (3) a diagnostic method involving isolating a sample from a female, determining whether the sample contains an entity (e1) to cause FSD, whether the entity has a direct or indirect effect on the level of activity of cAMP in the sexual genitalia of the female and whether the entity can be modulated to achieve a beneficial effect by using (a1); and (4) a diagnostic kit comprising device for detecting (e1) in an isolated female sample, and (a1). ACTIVITY : Endocrine-Gen. MECHANISM OF ACTION : Neutral endopeptidase (NEP) inhibitor; Mediator of female genital vasorelaxation. Test details are described but no results for the specific compounds given.

机译：包含中性内肽酶（NEP）（a1）抑制剂，载体，稀释剂或赋形剂（可选）以及其他药物（优选NEP，磷酸二酯酶（PDE）和/或神经肽Y（NPY）抑制剂）的药物组合物（C1）是新的。包括以下独立权利要求：（1）执行一种测定方法，以鉴定可用于治疗女性性功能障碍（FSD）的药物，包括确定该药物是否可以直接或间接增强3'，5'-单磷酸环腺苷（ cAMP）（其中cAMP在该试剂存在下增强）指示该试剂可用于治疗其中（a1）该试剂的FSD，确定至少一种可直接或间接增强cAMP的试剂，剂，将确定的剂与载体，稀释剂或赋形剂混合以形成（C1），然后包装（C1）; （2）鉴定可治疗FSD的药物的测定过程，包括将药物施用于动物模型，测量cAMP的任何增效作用和/或动物生殖器中血流量的增加，其中药物为（a1）和所述动物模型包括麻醉的雌性动物中的至少一种，其包括用于测量在刺激盆腔神经之后该动物的生殖器血流变化的装置，其中所述药剂在任选口服后增强性生殖器中的cAMP; （3）一种诊断方法，包括从女性中分离样品，确定样品中是否包含导致FSD的实体（e1），该实体是否对cAMP在性生殖器中的活性水平产生直接或间接影响。女性，以及是否可以通过使用（a1）调整实体以达到有益效果; （4）诊断试剂盒，其包括用于检测分离的雌性样品中的（e1）和（a1）的装置。活动：内分泌Gen。作用机理：中性内肽酶（NEP）抑制剂;女性生殖器血管舒张的介质。描述了测试细节，但没有给出特定化合物的结果。

著录项

公开/公告号PL343753A1

专利类型
公开/公告日2001-05-21

原文格式PDF
申请/专利权人 PFIZER INC.;
展开▼

申请/专利号PL20000343753
发明设计人 MAW GRAHAM NIGEL;WAYMAN CHRISTOPHER PETER;
展开▼

申请日2000-11-08
分类号A61K31/00;A61P15/00;
国家 PL
入库时间 2022-08-22 01:24:04

相似文献

专利
外文文献
中文文献